Musa, Sanjin and Catovic Baralija, Elma and Ivey Sawin, Veronica and Nardone, Anthony and Palo, Mirza and Skocibusic, Sinisa and Blazevic, Mia and Cilovic Lagarija, Seila and Ahmetovic-Karic, Gorana and Ljuca, Alma and Dostovic-Halilovic, Sanela and Nedic, Rozalija and Subissi, Lorenzo and Ibrahim, Rawi and Boshevska, Golubinka and Bergeri, Isabel and Pebody, Richard and Vaughan, Aisling (2023) Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies. Wiley online library, 17 (8). pp. 1-10.
![[thumbnail of Evolution of seroprevalence to SARS-CoV-2 in blood donors....pdf]](/style/images/fileicons/text.png) |
Text
Evolution of seroprevalence to SARS-CoV-2 in blood donors....pdf - Published Version Download (1MB) |
Abstract
Background: Sarajevo Canton in the Federation of Bosnia and Herzegovina has
recorded several waves of high SARS-CoV-2 transmission and has struggled to reach
adequate vaccination coverage. We describe the evolution of infection- and vaccine-
induced SARS-CoV-2 antibody response and persistence.
Methods: We conducted repeated cross-sectional analyses of blood donors aged
18–65 years in Sarajevo Canton in November–December 2020 and 2021. We ana-
lyzed serum samples for anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies.
To assess immune durability, we conducted longitudinal analyses of seropositive
participants at 6 and 12 months.
Results: One thousand fifteen participants were included in Phase 1 (November–
December 2020) and 1152 in Phase 2 (November–December 2021). Seropreva-
lence increased significantly from 19.2% (95% CI: 17.2%–21.4%) in Phase 1 to
91.6% (95% CI: 89.8%–93.1%) in Phase 2. Anti-S IgG titers were significantly
higher among vaccinated (58.5%) than unvaccinated infected participants across
vaccine products (p < 0.001), though highest among those who received an mRNA
vaccine. At 6 months, 78/82 (95.1%) participants maintained anti-spike seroposi-
tivity; at 12 months, 58/58 (100.0%) participants were seropositive, and
33 (56.9%) had completed the primary vaccine series within 6 months. Among
11 unvaccinated participants who were not re-infected at 12 months, anti-S IgG
declined from median 770.1 (IQR 615.0–1321.7) to 290.8 (IQR 175.7–400.3).
Anti-N IgG antibodies waned earlier, from 35.4% seropositive at 6 months to
24.1% at 12 months.
| Item Type: | Article |
|---|---|
| Subjects: | Medical and Health Sciences > Basic medicine Medical and Health Sciences > Clinical medicine Medical and Health Sciences > Health sciences Medical and Health Sciences > Other medical sciences |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Golubinka Bosevska |
| Date Deposited: | 02 Oct 2023 10:45 |
| Last Modified: | 02 Oct 2023 10:45 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/32296 |
Actions (login required)
 |
View Item |